Expression of APP, BACE1, AChE and ChAT in an AD model in rats and the effect of donepezil hydrochloride treatment

Li,Qiang; Chen,Min; Liu,Hongmin; Yang,Liqun; Yang,Guiying

doi:10.3892/mmr.2012.1102

Expression of APP, BACE1, AChE and ChAT in an AD model in rats and the effect of donepezil hydrochloride treatment

Authors:
- Qiang Li
- Min Chen
- Hongmin Liu
- Liqun Yang
- Guiying Yang
View Affiliations

Affiliations: Nursing School, Qiqihar Medical University, Qiqihar 161006, P.R. China, Medical Technology School, Qiqihar Medical University, Qiqihar 161006, P.R. China
Published online on: September 26, 2012 https://doi.org/10.3892/mmr.2012.1102
Pages: 1450-1454

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the pathological changes in a rat model of Alzheimer's disease (AD) and the effect of donepezil hydrochloride (HCl) treatment. The rat model of AD was established by the bilateral injection of amyloid β1-40 (Aβ1-40) into the hippocampus. Changes in spatial learning and memory functions were examined using the Morris water maze test and changes in catalase (CAT) and glutathione peroxidase (GSH-Px) activities were determined using chemical colorimetry. Moreover, the changes in acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) expression were analyzed using immunohistochemical staining. The mRNA expression levels of the amyloid precursor protein (APP) and β-secreted enzyme 1 (BACE1) were evaluated using RT-PCR. The effects of donepezil HCl on the aforementioned indices were also observed. The rat memories of the platform quadrants in the blank, sham and donepezil HCl groups were improved compared with those of the rats in the model group. The ratio of swim distance in the fourth platform quadrant (l4) to the total swim distance (l total) for the model group rats (l4/l total) was significantly decreased compared with that for the blank and sham group rats. Following donepezil HCl treatment, the ratio of l4/l total significantly increased. AD modeling caused a significant decrease in the CAT and GSH-Px activities in the brain tissues of the rats. The CAT and GSH-Px activities in the AD model rats significantly increased following donepezil HCl treatment. Moreover, donepezil HCl treatment significantly decreased the AChE, APP and BACE1 mRNA expression levels and increased the ChAT expression levels. Therefore, donepezil HCl was able to significantly decrease learning and memory damage in a rat model of AD.

View Figures

View References

1	Lee DY, Fletcher E, Martinez O, et al: Vascular and degenerative processes differentially affect regional interhemispheric connections in normal aging, mild cognitive impairment, and Alzheimer disease. Stroke. 41:1791–797. 2010. View Article : Google Scholar
2	Aluise CD, Robinson RA, Beckett TL, et al: Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis. 39:221–228. 2010. View Article : Google Scholar : PubMed/NCBI
3	Zhou ZD, Chan CH, Ma QH, Xu XH, Xiao ZC and Tan EK: The roles of amyloid precursor protein (APP) in neurogenesis: implications to pathogenesis and therapy of Alzheimer disease. Cell Adh Migr. 5:280–292. 2011. View Article : Google Scholar : PubMed/NCBI
4	Armstrong J, Boada M, Rey MJ, Vidal N and Ferrer I: Familial Alzheimer disease associated with A713T mutation in APP. Neurosci Lett. 370:241–243. 2004. View Article : Google Scholar : PubMed/NCBI
5	Esh C, Patton L, Kalback W, et al: Altered APP processing in PDAPP (Val717→Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry. 44:13807–13819. 2005.PubMed/NCBI
6	Ceballos-Picot I, Nicole A and Sinet PM: Cellular clones and transgenic mice overexpressing copper-zinc superoxide dismutase: models for the study of free radical metabolism and aging. EXS. 62:89–98. 1992.PubMed/NCBI
7	Moon EY, Oh JM, Kim YH, Ryoo IJ and Yoo ID: Clitocybins, novel isoindolinone free radical scavengers, from mushroom Clitocybe aurantiaca inhibit apoptotic cell death and cellular senescence. Biol Pharm Bull. 32:1689–1694. 2009. View Article : Google Scholar : PubMed/NCBI
8	Percy ME, Dalton AJ, Markovic VD, et al: Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease. Am J Med Genet. 35:459–467. 1990. View Article : Google Scholar
9	Loewenstein DA, Acevedo A, Czaja SJ and Duara R: Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors. Am J Geriatr Psychiatry. 12:395–402. 2004. View Article : Google Scholar
10	Lamirault L, Guillou C, Thal C and Simon H: (-)-9-Dehydrogalanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats. Neurobiol Learn Mem. 80:113–122. 2003. View Article : Google Scholar
11	Gibb WR, Mountjoy CQ, Mann DM and Lees AJ: Pathological study of the association between Lewy body disease and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 52:701–708. 1989.
12	Tohgi H, Abe T, Hashiguchi K, Saheki M and Takahashi S: Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett. 177:139–142. 1994. View Article : Google Scholar : PubMed/NCBI
13	Li J, Wang G, Liu J, et al: Puerarin attenuates amyloid-beta-induced cognitive impairment through suppression of apoptosis in rat hippocampus in vivo. Eur J Pharmacol. 649:195–201. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kim JW, Lee DY, Choo IH, et al: Microstructural alteration of the anterior cingulum is associated with apathy in Alzheimer disease. Am J Geriatr Psychiatry. 19:644–653. 2011. View Article : Google Scholar : PubMed/NCBI
15	Saber AJ and Cain DP: Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists. Neuropsychopharmacology. 28:1247–1256. 2003. View Article : Google Scholar
16	Wang L, Khan A, Csernansky JG, et al: Fully-automated, multi-stage hippocampus mapping in very mild Alzheimer disease. Hippocampus. 19:541–548. 2009. View Article : Google Scholar : PubMed/NCBI
17	Polidori MC and Mecocci P: Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis. 4:517–522. 2002.PubMed/NCBI
18	Moreira PI, Sayre LM, Zhu X, Nunomura A, Smith MA and Perry G: Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. Methods Mol Biol. 610:419–434. 2010. View Article : Google Scholar : PubMed/NCBI
19	Aksenov MY, Tucker HM, Nair P, et al: The expression of key oxidative stress-handling genes in different brain regions in Alzheimer’s disease. J Mol Neurosci. 11:151–164. 1998.PubMed/NCBI
20	Evereklioglu C, Er H, Doganay S, et al: Nitric oxide and lipid peroxidation are increased and associated with decreased antioxidant enzyme activities in patients with age-related macular degeneration. Doc Ophthalmol. 106:129–136. 2003. View Article : Google Scholar
21	Bales KR, Tzavara ET, Wu S, et al: Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest. 116:825–832. 2006. View Article : Google Scholar : PubMed/NCBI
22	Xiao F, Li XG, Zhang XY, et al: Combined administration of D-galactose and aluminium induces Alzheimer-like lesions in brain. Neurosci Bull. 27:143–155. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lestaevel P, Bensoussan H, Racine R, Airault F, Gourmelon P and Souidi M: Transcriptomic effects of depleted uranium on acetylcholine and cholesterol metabolisms in Alzheimer’s disease model. C R Biol. 334:85–90. 2011.PubMed/NCBI
24	Sultana R, Robinson RA, Di Domenico F, et al: Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age. J Proteomics. 74:2430–2440. 2011. View Article : Google Scholar
25	Monji A, Utsumi H, Ueda T, et al: Amyloid-beta-protein (A beta) (25–35)-associated free radical generation is strongly influenced by the aggregational state of the peptides. Life Sci. 70:833–841. 2002.
26	Tamaoka A, Fraser PE, Ishii K, et al: Amyloid-beta-protein isoforms in brain of subjects with PS1-linked, beta APP-linked and sporadic Alzheimer disease. Brain Res Mol Brain Res. 56:178–185. 1998. View Article : Google Scholar : PubMed/NCBI
27	Jeong SJ, Kim K and Suh YH: Age-related changes in the expression of Alzheimer’s beta APP in the brain of senescence accelerated mouse (SAM)-P/10. Neuroreport. 8:1733–1737. 1997.
28	Mishra S and Caflisch A: Dynamics in the active site of β-secretase: a network analysis of atomistic simulations. Biochemistry. 50:9328–9339. 2011.
29	Singer O, Marr RA, Rockenstein E, et al: Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 8:1343–1349. 2005. View Article : Google Scholar : PubMed/NCBI